KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Cme (CME) EBITDA (2016 - 2026)

Cme has reported EBITDA over the past 18 years, most recently at $1.3 billion for Q1 2026.

  • Quarterly EBITDA rose 17.76% to $1.3 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.5 billion through Mar 2026, up 8.36% year-over-year, with the annual reading at $4.2 billion for FY2025, 7.58% up from the prior year.
  • EBITDA was $1.3 billion for Q1 2026 at Cme, up from $1.0 billion in the prior quarter.
  • Over five years, EBITDA peaked at $1.3 billion in Q1 2026 and troughed at $668.3 million in Q4 2022.
  • The 5-year median for EBITDA is $947.1 million (2024), against an average of $959.6 million.
  • Biggest five-year swings in EBITDA: grew 29.16% in 2023 and later decreased 5.07% in 2025.
  • Tracing CME's EBITDA over 5 years: stood at $668.3 million in 2022, then rose by 29.16% to $863.2 million in 2023, then increased by 9.72% to $947.1 million in 2024, then rose by 7.65% to $1.0 billion in 2025, then surged by 31.12% to $1.3 billion in 2026.
  • According to Business Quant data, EBITDA over the past three periods came in at $1.3 billion, $1.0 billion, and $999.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.